The work could lead to targeted therapies that prevent life threatening clots happening in future.
Irish scientists have identified how and why some Covid-19 patients can develop life-threatening blood clots.
The work ,led by researchers at the Royal College of Surgeons in Ireland , could lead to targeted therapies that prevent such clots happening in future.The scientists analysed samples from Covid-19 patients in intensive care in the Beaumont Hospital in Dublin. They found the balance between a molecule that causes clotting called the von Willebrand Factor and its regulator, ADANTS 13, is severely disrupted in Covid patients who had elevated levels of the VWF protein.
She said more research needed to be done to determine whether targets aimed at correcting the levels of ADAMTS 13 and VWF can lead to successful interventions."Vaccines will continue to be unavailable to many people throughout the world and it is important that we provide effective treatments to them and to those with breakthrough infections."
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
YouTube suspends GOP Sen. Ron Johnson's account, says he violated Covid-19 policyYouTube suspended Sen. Ron Johnson’s account on Friday after the Wisconsin Republican posted his recent remarks about alternative therapies to treat Covid-19.
Read more »
Novavax COVID-19 vaccine more than 90% effective in U.S. trialNovavax Inc (NVAX.O) on Monday reported late-stage data from its U.S.-based clinical trial showing its vaccine is more than 90% effective against COVID-19 across a variety of variants of the virus.
Read more »
Novavax announces its COVID-19 vaccine is over 90% effective against symptomatic diseaseJUST IN: American biotechnology company Novavax announces that its experimental COVID-19 vaccine is more than 90% effective against symptomatic disease in late-stage clinical trials.
Read more »
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said.
Read more »
Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trialJUST IN: Novavax says its coronavirus vaccine has an overall efficacy of 90.4% and was 'generally well-tolerated' in a Phase 3 trial in the US and Mexico
Read more »